Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
IPO Year: 2018
Exchange: NASDAQ
Website: osmotica.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2021 | $5.00 | Buy | HC Wainwright & Co. |
| 11/9/2021 | $7.00 | Buy | Jefferies |
| 9/24/2021 | $6.00 | Overweight | Cantor Fitzgerald |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. initiated coverage of Osmotica Pharmaceuticals with a rating of Buy and set a new price target of $5.00
Jefferies resumed coverage of Osmotica Pharmaceuticals with a rating of Buy and set a new price target of $7.00
Cantor Fitzgerald initiated coverage of Osmotica Pharmaceuticals with a rating of Overweight and set a new price target of $6.00
RBC Capital Mkts resumed coverage of Osmotica Pharmaceuticals with a rating of Outperform and set a new price target of $8.00
RBC Capital reiterated coverage of Osmotica Pharmaceuticals with a rating of Outperform and set a new price target of $8.00 from $12.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
Fastest customizable press release news feed in the world
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in February 2022 -- -- Company to host video webcast at 8:30am ET on January 19, 2022 -- BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("OSMT" or the "Company"), a specialty pharmaceutical company, announced today that the Company has changed its name to RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL"). This rebranding reflects RVL's strategy to become a growth comp
-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper -- Bridgewater, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer and James "JD" Schaub, Chief Operating Officer, will host a video webcast to discuss recent UPNEEQ® trends, pending expansion into the medical aesthetics market and other general business updates. Dr. Jackie Yee is board-certified in Plastic and Reconstructive Surgery and speciali
BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows: Date:Wednesday, January 19, 2022Time:8:30 a.m. ETWebcast:https://experience.v-unite.com/#/aestheticrecorddemo/rvlinvestorday/room/welcome The webcast will be available thereafter via the Company's website at www.rvlpharma.com under the "Investor & News
BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows: Date:Monday, January 10, 2022On Demand Time:7:00AM ETWebcast:https://journey.ct.events/view/b39a70c0-7058-4a1f-ba97-e18b13918fc7 The presentation will be webcast on-demand and available for 30 days thereafter using the link provided above and via the Company's website at www.osmotica.com under t
Third quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales Expansion of Upneeq launch continues with introduction of Direct Dispense program in eyecare and formation of Aesthetics business unit Sale of legacy business and capital raises streamlined business and strengthened balance sheet BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced business highlights and financial results for the three months ended September 30, 2021. "With the sale of our legacy business, we have accomplished our strategic goal of transformin
BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows: Date:Thursday, November 18, 2021On Demand Time:8:00AM GMT (3:00AM ET)Webcast:https://wsw.com/webcast/jeff201/osmt/1869930 The presentation will be webcast on-demand and available for 30 days thereafter using the link provided above and via the Company's website at www.osmotica.com under the "Investo
BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: DateMonday, November 15, 2021Time4:30 p.m. ETToll free (U.S.)(866) 672-5029International(409) 217-8312Conference ID57399556Webcast (live and replay)www.osmotica.com under the "Investor & News" section
BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company granted the underwriter a 30-day option to purchase up to an additional 2,100,000 ordinar
BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by Athyrium Capital Management ("Athyrium"). "This financing provides the Company with additional cash to support the commercialization of Upneeq®," stated Brian Markison, Chief Executive Officer. "We are excited to have Athyrium, a leading health care investor, as our financial partner." "We are thrilled to partner with the Osmotica team and to provide capital to support the commercial effort
BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to additional 2,100,000 ordinary shares and/or addit
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)
EFFECT - Osmotica Pharmaceuticals plc (0001739426) (Filer)
DEF 14A - Osmotica Pharmaceuticals plc (0001739426) (Filer)
8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)
S-8 - Osmotica Pharmaceuticals plc (0001739426) (Filer)
8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)
10-Q - Osmotica Pharmaceuticals plc (0001739426) (Filer)
8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)
S-3 - Osmotica Pharmaceuticals plc (0001739426) (Filer)
Live finance-specific insights
BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: DateMonday, November 15, 2021Time4:30 p.m. ETToll free (U.S.)(866) 672-5029International(409) 217-8312Conference ID57399556Webcast (live and replay)www.osmotica.com under the "Investor & News" section
BRIDGEWATER, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 second quarter financial results on Monday, August 16, 2021, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: Date Monday, August 16, 2021Time 4:30 p.m. ETToll free (U.S.) (866) 672-5029International (409) 217-8312Conference ID 1278168Webcast (live and replay) www.osmotica.com under the "Investor &
This live feed shows all institutional transactions in real time.
SC 13D/A - Osmotica Pharmaceuticals plc (0001739426) (Subject)
SC 13G - Osmotica Pharmaceuticals plc (0001739426) (Subject)
SC 13D/A - Osmotica Pharmaceuticals plc (0001739426) (Subject)
SC 13G/A - Osmotica Pharmaceuticals plc (0001739426) (Subject)